Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
1. |
ECCT/26/04/02 | IGHID 12430/DELIVER-02 IGHID12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research Centre(MUCRC), Eldoret, Kenya (Uasin Gishu county) 2. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county) |
View |
2. |
ECCT/26/03/02 | E-MASTER STUDY: PHASE 1 Diagnosis of postpartum haemorrhage at caesarean section: a multi-country diagnostic and prognostic accuracy study (E-MASTER: PHASE 1) |
Principal Investigator(s) 1. Zahida Qureshi 2. Alfred Osoti 3. George Gwako Site(s) in Kenya 1. St Marys Mission Hospital-Langata (Nairobi City county) 2. Mbagathi County Referral Hospital (Nairobi City county) |
View |
3. |
ECCT/26/03/01 | C1091009 Study A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute Kisumu County Referral Hospital (Kisumu county) 2. KEMRI Butere Clinical Research Centre (Kakamega county) 3. Kenya Medical Research Institute Walter Reed Project (Kericho county) 4. Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research (Kisumu county) |
View |
4. |
ECCT/26/02/08 | SOAR Study Optimizing Smoking Cessation and Unhealthy Alcohol Use Treatment Among People Living with Human Immunodeficiency Virus (PLWH) In Nairobi, Kenya Abbreviated as SOAR Study Smoking cessation Optimization and unhealthy Alcohol use Research, SOAR, Study. |
Principal Investigator(s) 1. DR. EMILY KOECH Site(s) in Kenya Riruta Hospital |
View |
5. |
ECCT/26/02/07 | IMPAACT 2024 Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV |
Principal Investigator(s) 1. LUCY Chepkurui Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project(KEMRI/WRP) |
View |